thalidomide has been researched along with Xeroderma in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors." | 2.53 | Paraneoplastic Itch Management. ( Rowe, B; Yosipovitch, G, 2016) |
| "In thalidomide-treated SSc patients, plasma levels of IL-12 and TNF-alpha increased, while plasma IL-5 and IL-10 levels remained unchanged." | 1.31 | Immune stimulation in scleroderma patients treated with thalidomide. ( Kaplan, G; Moreira, A; Oliver, SJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rowe, B | 1 |
| Yosipovitch, G | 1 |
| Oliver, SJ | 1 |
| Moreira, A | 1 |
| Kaplan, G | 1 |
1 review available for thalidomide and Xeroderma
| Article | Year |
|---|---|
Paraneoplastic Itch Management.
Topics: Acantholysis; Acanthosis Nigricans; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Apre | 2016 |
1 other study available for thalidomide and Xeroderma
| Article | Year |
|---|---|
Immune stimulation in scleroderma patients treated with thalidomide.
Topics: Adjuvants, Immunologic; Adult; Aged; Female; Gastroesophageal Reflux; Hematopoietic Cell Growth Fact | 2000 |